DOCSLIB.ORG

Of the T Cell by G-CSF and IL-10 Cell Mobilization Requires Direct

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Downloaded from http://www.jimmunol.org/ by guest on September 26, 2021 is online at: average * The Journal of Immunology , 26 of which you can access for free at: 2014; 192:3180-3189; Prepublished online 28 from submission to initial decision 4 weeks from acceptance to publication February 2014; doi: 10.4049/jimmunol.1302315 http://www.jimmunol.org/content/192/7/3180 Modification of T Cell Responses by Stem Cell Mobilization Requires Direct Signaling of the T Cell by G-CSF and IL-10 Kelli P. A. MacDonald, Laetitia Le Texier, Ping Zhang, Helen Morris, Rachel D. Kuns, Katie E. Lineburg, Lucie Leveque, Alistair L. Don, Kate A. Markey, Slavica Vuckovic, Frederik O. Bagger, Glen M. Boyle, Bruce R. Blazar and Geoffrey R. Hill J Immunol cites 45 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2014/02/28/jimmunol.130231 5.DCSupplemental This article http://www.jimmunol.org/content/192/7/3180.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 26, 2021. The Journal of Immunology Modification of T Cell Responses by Stem Cell Mobilization Requires Direct Signaling of the T Cell by G-CSF and IL-10 Kelli P. A. MacDonald,* Laetitia Le Texier,* Ping Zhang,* Helen Morris,* Rachel D. Kuns,* Katie E. Lineburg,* Lucie Leveque,* Alistair L. Don,* Kate A. Markey,* Slavica Vuckovic,* Frederik O. Bagger,† Glen M. Boyle,* Bruce R. Blazar,‡ and Geoffrey R. Hill*,x The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mobilized peripheral blood stem cells. G-CSF has diverse biological effects on a broad range of cells and IL-10 is a key regulator of many of these effects. Using mixed radiation chimeras in which the hematopoietic or nonhematopoietic compartments were wild-type, IL-102/2, G-CSFR2/2,or combinations thereof we demonstrated that the attenuation of alloreactive T cell responses after G-CSF mobilization required Downloaded from direct signaling of the T cell by both G-CSF and IL-10. IL-10 was generated principally by radio-resistant tissue, and was not required to be produced by T cells. G-CSF mobilization significantly modulated the transcription profile of CD4+CD25+ regula- tory T cells, promoted their expansion in the donor and recipient and their depletion significantly increased graft-versus-host disease (GVHD). In contrast, stem cell mobilization with the CXCR4 antagonist AMD3100 did not alter the donor T cell’s ability to induce acute GVHD. These studies provide an explanation for the effects of G-CSF on T cell function and demonstrate that IL- 10 is required to license regulatory function but T cell production of IL-10 is not itself required for the attenuation GVHD. http://www.jimmunol.org/ Although administration of CXCR4 antagonists is an efficient means of stem cell mobilization, this fails to evoke the immuno- modulatory effects seen during G-CSF mobilization. These data provide a compelling rationale for considering the immunological benefits of G-CSF in selecting mobilization protocols for allogeneic stem cell transplantation. The Journal of Immunology, 2014, 192: 3180–3189. raft-versus-host disease (GVHD) remains a major com- (1, 2). T cells from donors treated with G-CSF have a reduced plication following allogeneic hematopoietic stem cell capacity to induce GVHD on a per cell basis relative to those from transplantation, with the resultant multiorgan damage control-treated donors (3). The mechanism by which G-CSF pre- G by guest on September 26, 2021 and immune deficiency significantly impairing overall transplant vents GVHD has been suggested to be the result of Th2 and reg- survival. The use of recombinant human G-CSF–mobilized stem ulatory T cells (Treg) differentiation of naive donor T cells (3, 4). cell grafts has lead to rapid immune and hematopoietic reconsti- There is additional data suggesting G-CSF may also reduce GVHD tution, and superior short term and long term disease free survival through effects on dendritic cells, monocytes and NK cells (reviewed in Ref. 4). Indeed, the attenuation of T cell function by G-CSF is *QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Aus- generally thought to be an indirect effect via effects on these in- tralia; †Department of Biology, Finsen Laboratory, Rigshospitalet, Faculty of Health nate cells. Sciences, Biotech Research and Innovation Centre, University of Copenhagen, We have previously demonstrated that pegylated G-CSF is su- Copenhagen, DK-2200 Denmark; ‡Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minne- perior to standard G-CSF for the prevention of GVHD, due to apolis, MN 55455; and xDepartment of Bone Marrow Transplantation, Royal Bris- the enhanced generation of IL-10–producing Treg (5). Indeed, bane Hospital, Brisbane, Queensland 4006, Australia the induction of Th2 cells and Tregs by G-CSF are well de- Received for publication September 5, 2013. Accepted for publication January 30, scribed and dependent on the dose and type of G-CSF molecule 2014. used (3, 4, 6). In these studies, we investigated the greater unan- This work was supported by grants from the National Health and Medical Research Council and Cancer Council Queensland. K.P.A.M. is a Cancer Council Queensland swered question surrounding how T cell function is modified by Senior Research Fellow. G.R.H. is a National Health and Medical Research Council G-CSF and whether these effects are recapitulated by mobilization Australian Fellow and Queensland Health Senior Clinical Research Fellow. K.A.M. with CXCR4 antagonists, which are also used for stem cell mo- is a National Health and Medical Research Council Clinical Training Fellow. bilization. K.P.A.M. designed and performed experiments, analyzed data, and wrote the manu- script; L.L.T., P.Z., H.M., L.L., and S.V. performed experiments; R.D.K., K.E.L., K.A.M., and A.L.D. assisted with experimental work, animal breeding, and moni- Materials and Methods toring; F.O.B. and G.M.B. assisted with microarray analysis; B.R.B. provided critical review of data and manuscript; and G.R.H. assisted with experimental design, data Mice analysis, and manuscript preparation. Female C57BL/6 (B6.WT, H-2b, CD45.2+), B6.Ptprca (H-2b, CD45.1+), b/d + Address correspondence and reprint requests to Dr. Kelli P. A. MacDonald, QIMR and B6D2F1 (H-2 , CD45.2 ) mice were purchased from the Animal Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Aus- Resources Centre (Perth, WA, Australia). B6.IL-102/2 (H-2b) and B6.G- tralia. E-mail address: [email protected] CSFR2/2 (H-2b) were supplied from the Australian National University The online version of this article contains supplemental material. and D. Link (Washington University, St. Louis, MO), respectively. Abbreviations used in this article: B6, C57BL/6; BM, bone marrow; DC, dendritic B6.Foxp3-eGFP, B6.Foxp3-GFP-Luciferase-DTR (B6.Foxp3-luci), and CD402/2 mice were supplied by the QIMR Berghofer Medical Research cell; GVHD, graft-versus-host disease; nTreg, natural regulatory T cell; Treg, regula- tory T cell. Institute animal facility. The mice were used between 8 and 12 wk of age. Mice were housed in sterilized microisolator cages and received acidified Copyright Ó 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.00 autoclaved water (pH 2.5) after transplantation. www.jimmunol.org/cgi/doi/10.4049/jimmunol.1302315 The Journal of Immunology 3181 Stem cell mobilization irradiated (1000 cGy) B6.WT or B6.IL-102/2 recipients, which were then allowed to reconstitute over 4 mo before use as allograft recipients. Recombinant human pegylated-G-CSF (Amgen, Thousand Oaks, CA) was In some experiments, a combination of both B6.WT and B6.IL-102/2 or diluted with normal saline (Baxter, Deerfield, IL) and given as a single dose B6.WT and B6.G-CSFR2/2 BM cells were transplanted in 1:1 or 4:1 ratios 2 6 s.c. at 12 mg/animal on day 6 prior to transplant (5). AMD3100 (Sigma- (5 3 10 cell total) as described in figures. The degree of systemic GVHD Aldrich, St. Louis, MO) was diluted with PBS and given s.c. at 200 mg/ was assessed by scoring as previously described (maximum index = 10) 2 animal per dose (7). Donor mice received AMD3100 or saline on days 4, (11). 23, 22, and 21at24-hintervals,andspleenswereharvested1hafter the last injection. All donor spleens were harvested on day 0. Where Cell preparation indicated, natural Treg (nTreg) were depleted in vivo by i.p. administration of anti-CD25 mAb (PC61) during G-CSF mobilization at days 23 and 21 T cells were purified using magnetic bead depletion of non-T cell pretransplant. splenocytes. Briefly, following red cell lysis, splenocytes were incu- bated with purified mAb (CD19, B220, Gr-1, CD11b, and Ter119). After Stem cell transplantation incubation with Abs, cells were incubated with goat anti-rat IgG BioMag beads (Qiagen Pty, Chadstone Centre, VIC, Australia) for 20 Mice were transplanted as described previously (5, 8, 9).
Recommended publications
  • Investigating the Genetic Basis of Cisplatin-Induced Ototoxicity in Adult South African Patients

    Investigating the Genetic Basis of Cisplatin-Induced Ototoxicity in Adult South African Patients

    --------------------------------------------------------------------------- Investigating the genetic basis of cisplatin-induced ototoxicity in adult South African patients --------------------------------------------------------------------------- by Timothy Francis Spracklen SPRTIM002 SUBMITTED TO THE UNIVERSITY OF CAPE TOWN In fulfilment of the requirements for the degree MSc(Med) Faculty of Health Sciences UNIVERSITY OF CAPE TOWN University18 December of Cape 2015 Town Supervisor: Prof. Rajkumar S Ramesar Co-supervisor: Ms A Alvera Vorster Division of Human Genetics, Department of Pathology, University of Cape Town 1 The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town Declaration I, Timothy Spracklen, hereby declare that the work on which this dissertation/thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university. I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever. Signature: Date: 18 December 2015 ' 2 Contents Abbreviations ………………………………………………………………………………….. 1 List of figures …………………………………………………………………………………... 6 List of tables ………………………………………………………………………………….... 7 Abstract ………………………………………………………………………………………… 10 1. Introduction …………………………………………………………………………………. 11 1.1 Cancer …………………………………………………………………………….. 11 1.2 Adverse drug reactions ………………………………………………………….. 12 1.3 Cisplatin …………………………………………………………………………… 12 1.3.1 Cisplatin’s mechanism of action ……………………………………………… 13 1.3.2 Adverse reactions to cisplatin therapy ……………………………………….
  • MBNL1 Regulates Essential Alternative RNA Splicing Patterns in MLL-Rearranged Leukemia

    MBNL1 Regulates Essential Alternative RNA Splicing Patterns in MLL-Rearranged Leukemia

    ARTICLE https://doi.org/10.1038/s41467-020-15733-8 OPEN MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia Svetlana S. Itskovich1,9, Arun Gurunathan 2,9, Jason Clark 1, Matthew Burwinkel1, Mark Wunderlich3, Mikaela R. Berger4, Aishwarya Kulkarni5,6, Kashish Chetal6, Meenakshi Venkatasubramanian5,6, ✉ Nathan Salomonis 6,7, Ashish R. Kumar 1,7 & Lynn H. Lee 7,8 Despite growing awareness of the biologic features underlying MLL-rearranged leukemia, 1234567890():,; targeted therapies for this leukemia have remained elusive and clinical outcomes remain dismal. MBNL1, a protein involved in alternative splicing, is consistently overexpressed in MLL-rearranged leukemias. We found that MBNL1 loss significantly impairs propagation of murine and human MLL-rearranged leukemia in vitro and in vivo. Through transcriptomic profiling of our experimental systems, we show that in leukemic cells, MBNL1 regulates alternative splicing (predominantly intron exclusion) of several genes including those essential for MLL-rearranged leukemogenesis, such as DOT1L and SETD1A.Wefinally show that selective leukemic cell death is achievable with a small molecule inhibitor of MBNL1. These findings provide the basis for a new therapeutic target in MLL-rearranged leukemia and act as further validation of a burgeoning paradigm in targeted therapy, namely the disruption of cancer-specific splicing programs through the targeting of selectively essential RNA binding proteins. 1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 2 Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 3 Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
  • Down Regulation of Membrane-Bound Neu3 Constitutes a New

    Down Regulation of Membrane-Bound Neu3 Constitutes a New

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Publications of the IAS Fellows IJC International Journal of Cancer Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells Chandan Mandal1, Cristina Tringali2, Susmita Mondal1, Luigi Anastasia2, Sarmila Chandra3, Bruno Venerando2 and Chitra Mandal1 1 Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, A Unit of Council of Scientific and Industrial Research, Govt of India, 4, Raja S. C. Mullick Road, Kolkata 700032, India 2 Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan, and IRCCS Policlinico San Donato, San Donato, Milan, Italy 3 Department of Hematology, Kothari Medical Centre, Kolkata 700027, India Membrane-linked sialidase Neu3 is a key enzyme for the extralysosomal catabolism of gangliosides. In this respect, it regulates pivotal cell surface events, including trans-membrane signaling, and plays an essential role in carcinogenesis. In this report, we demonstrated that acute lymphoblastic leukemia (ALL), lymphoblasts (primary cells from patients and cell lines) are characterized by a marked down-regulation of Neu3 in terms of both gene expression (230 to 40%) and enzymatic activity toward ganglioside GD1a (225.6 to 30.6%), when compared with cells from healthy controls. Induced overexpression of Neu3 in the ALL-cell line, MOLT-4, led to a significant increase of ceramide (166%) and to a parallel decrease of lactosylceramide (255%). These events strongly guided lymphoblasts to apoptosis, as we assessed by the decrease in Bcl2/ Bax ratio, the accumulation of Neu3 transfected cells in the sub G0–G1 phase of the cell cycle, the enhanced annexin-V positivity, the higher cleavage of procaspase-3.
  • Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling

    Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling

    UC Davis UC Davis Previously Published Works Title Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling. Permalink https://escholarship.org/uc/item/0nk8n7xb Journal Scientific reports, 6(1) ISSN 2045-2322 Authors Arabyan, Narine Park, Dayoung Foutouhi, Soraya et al. Publication Date 2016-07-08 DOI 10.1038/srep29525 Peer reviewed eScholarship.org Powered by the California Digital Library University of California www.nature.com/scientificreports OPEN Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling Received: 09 February 2016 Narine Arabyan1, Dayoung Park2, Soraya Foutouhi1, Allison M. Weis1, Bihua C. Huang1, Accepted: 17 June 2016 Cynthia C. Williams2, Prerak Desai1,†, Jigna Shah1,‡, Richard Jeannotte1,3,§, Nguyet Kong1, Published: 08 July 2016 Carlito B. Lebrilla2,4 & Bart C. Weimer1 Complex glycans cover the gut epithelial surface to protect the cell from the environment. Invasive pathogens must breach the glycan layer before initiating infection. While glycan degradation is crucial for infection, this process is inadequately understood. Salmonella contains 47 glycosyl hydrolases (GHs) that may degrade the glycan. We hypothesized that keystone genes from the entire GH complement of Salmonella are required to degrade glycans to change infection. This study determined that GHs recognize the terminal monosaccharides (N-acetylneuraminic acid (Neu5Ac), galactose, mannose, and fucose) and significantly (p < 0.05) alter infection. During infection, Salmonella used its two GHs sialidase nanH and amylase malS for internalization by targeting different glycan structures. The host glycans were altered during Salmonella association via the induction of N-glycan biosynthesis pathways leading to modification of host glycans by increasing fucosylation and mannose content, while decreasing sialylation.
  • Molecular Genetics of Microcephaly Primary Hereditary: an Overview

    Molecular Genetics of Microcephaly Primary Hereditary: an Overview

    brain sciences Review Molecular Genetics of Microcephaly Primary Hereditary: An Overview Nikistratos Siskos † , Electra Stylianopoulou †, Georgios Skavdis and Maria E. Grigoriou * Department of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece; [email protected] (N.S.); [email protected] (E.S.); [email protected] (G.S.) * Correspondence: [email protected] † Equal contribution. Abstract: MicroCephaly Primary Hereditary (MCPH) is a rare congenital neurodevelopmental disorder characterized by a significant reduction of the occipitofrontal head circumference and mild to moderate mental disability. Patients have small brains, though with overall normal architecture; therefore, studying MCPH can reveal not only the pathological mechanisms leading to this condition, but also the mechanisms operating during normal development. MCPH is genetically heterogeneous, with 27 genes listed so far in the Online Mendelian Inheritance in Man (OMIM) database. In this review, we discuss the role of MCPH proteins and delineate the molecular mechanisms and common pathways in which they participate. Keywords: microcephaly; MCPH; MCPH1–MCPH27; molecular genetics; cell cycle 1. Introduction Citation: Siskos, N.; Stylianopoulou, Microcephaly, from the Greek word µικρoκεϕαλi´α (mikrokephalia), meaning small E.; Skavdis, G.; Grigoriou, M.E. head, is a term used to describe a cranium with reduction of the occipitofrontal head circum- Molecular Genetics of Microcephaly ference equal, or more that teo standard deviations
  • Thesis Layout 3

    Thesis Layout 3

    University of Groningen Gestational diabetes mellitus and fetoplacental vasculature alterations Silva Lagos, Luis DOI: 10.33612/diss.113056657 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Silva Lagos, L. (2020). Gestational diabetes mellitus and fetoplacental vasculature alterations: Exploring the role of adenosine kinase in endothelial (dys)function. University of Groningen. https://doi.org/10.33612/diss.113056657 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 26-09-2021 Adenosine kinase and cardiovascular fetal programming in gestational diabetes mellitus Luis Silva1,2, Torsten Plösch3, Fernando Toledo1,4, Marijke M. Faas2,3, Luis Sobrevia1,5,6 1 Cellular and Molecular Physiology Laboratory (CMPL), Department of Obstetrics, Division of Obstetrics and Gynaecology, School of Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile.
  • Characterization of the Human Sialidase Neu4 Gene Promoter

    Characterization of the Human Sialidase Neu4 Gene Promoter

    Turkish Journal of Biology Turk J Biol (2014) 38: 574-580 http://journals.tubitak.gov.tr/biology/ © TÜBİTAK Research Article doi:10.3906/biy-1401-63 Characterization of the human sialidase Neu4 gene promoter 1, 2 Volkan SEYRANTEPE *, Murat DELMAN 1 Department of Molecular Biology and Genetics, İzmir Institute of Technology, Urla İzmir, Turkey 2 Biotechnology and Bioengineering Graduate Program, İzmir Institute of Technology, Urla, İzmir, Turkey Received: 21.01.2014 Accepted: 08.05.2014 Published Online: 05.09.2014 Printed: 30.09.2014 Abstract: There are 4 different sialidases that have been described in humans: lysosomal (Neu1), cytoplasmic (Neu2), plasma membrane (Neu3), and lysosomal/mitochondrial (Neu4). Previously, we have shown that Neu4 has a broad substrate specificity and is active against glyco-conjugates, including GM2 ganglioside, at the acidic pH of 3.2. An overexpression of Neu4 in transfected neuroglia cells from a Tay–Sachs patient shows a clearance of accumulated GM2, indicating the biological importance of Neu4. In this paper, we aimed to characterize a minimal promoter region of the human Neu4 gene in order to understand the molecular mechanism regulating its expression. We cloned 7 different DNA fragments from the human Neu4 promoter region into luciferase expression vectors for a reporter assay and also performed an electrophoretic mobility shift assay to demonstrate the binding of transcription factors. We demonstrated that –187 bp upstream of the Neu4 gene is a minimal promoter region for controlling transcription from the human Neu4 gene. The electrophoretic mobility shift assay showed that the minimal promoter region recruits a c-myc transcription factor, which might be responsible for regulation of Neu4 gene transcription.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20120149714A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0149714 A1 Heise et al. (43) Pub. Date: Jun. 14, 2012 (54) EFFECTS OF INHIBITORS OF FGFR3 ON (60) Provisional application No. 60/748,944, ?led on Dec. GENE TRANSCRIPTION 8, 2005. (76) Inventors: Carla Heise, Benicia, CA (US); Publication Classi?cation Esther Masih-Khan, Ontario (CA); 51 I Cl Edward Moler Walnut Creek CA ( ) nt' ' (US); Michael. Rowe,’ Oakland,’ CA A61K 31/497 (2006.01) (US),_ Keith. Stewart, Scottsdale, G01N 33/53 (2006.01) AZ (US) Suzanne Trudel Ontario G01N 33/566 (200601) (CA) ’ ’ C12Q 1/68 (2006.01) (52) US. Cl. ................ .. 514/253.07; 435/611; 435/612; (21) Appl. No.: 13/400,833 435/79; 435/792; 436/501 (22) Filed: Feb. 21, 2012 (57) ABSTRACT Related U‘s‘ Application Data Methods of utilizing blomarkers to 1dent1fy patients for treat ment or to momtor response to treatment are taught herein. (62) Division of application No, 12/096,222, ?led on Jun, Alterations in levels of gene expression of the biomarkers, 19, 2008, now Pat. No. 8,158,360, ?led as application particularly in response to FGFR3 inhibition, are measured No. PCT/US2006/061766 on Dec. 7, 2006. and identi?cations or adjustments may be made accordingly. US 2012/0149714 A1 Jun. 14, 2012 EFFECTS OF INHIBITORS OF FGFR3 ON [0007] An individual’s response to a particular treatment or GENE TRANSCRIPTION predisposition to disease and the correlation to a particular gene of interest has been documented. It is noW believed that BACKGROUND OF THE INVENTION cancer chemotherapy is limited by the predisposition of spe ci?c populations to drug toxicity or poor drug response.
  • Supplemental Figures

    Supplemental Figures

    Supplemental Figures Development of a new macrophage-specific TRAP mouse (MacTRAP) and definition of the renal macrophage translational signature Andreas Hofmeister, Maximilian C. Thomassen, Sabrina Markert, André Marquardt, Mathieu Preußner, Martin Rußwurm, Ralph Schermuly, Ulrich Steinhoff, Hermann-Josef Gröne, Joachim Hoyer, Benjamin D. Humphreys, Ivica Grgic Correspondence: Ivica Grgic MD, Klinikum der Philips-Universität Marburg, Baldingerstrasse 1, 35043 Marburg. Phone: +4964215861736, email: [email protected] Sup. Fig. S1 Δ6.7fmsGFP-L10a plasmid (pGL2 backbone) Sup. Fig. S1: Plasmid map of the engineered c-fms-eGFP-L10a expression vector. Mlu1/Sal1 digestion was used for linearization and extraction of the transgene. Sup. Fig. S2 A Neutrophils Monocytes Lymphocytes B Monocytes Monocytes Neutrophils Lymphocytes H - TRAP Ly6g Count FSC CD115 Mac GFP GFP GFP GFP H - Ly6g Count FSC CD115 Wild Wild type GFP GFP GFP GFP Sup. Fig. S2: FACS analysis detects eGFP-L10a signals in monocytes but not in neutrophils or lymphocytes isolated from peripheral blood of MacTRAP mice. (A) Gating strategy to define monocyte, neutrophil and lymphocyte populations. Only single cells contributed to the analysis. (B) GFP-fluorescence was specifically detected in CD115+ monocytes, but not in Ly6g+ neutrophils or lymphocytes of MacTRAP mice. Blood samples from wild-type mice served as negative controls. Representative plots are shown, n=6. Sup. Fig. S3 A eGFP-L10a Ly6g merge+DAPI kidney 7d UUO B eGFP-L10a Ly6g merge+DAPI incision skin Tail Sup. Fig. S3: Immunostaining for mature neutrophils in fibrotic kidney tissue and tail skin biopsies from MacTRAP mice. (A) Only a very small fraction of Ly6g+ neutrophils is positive for eGFP-L10a in fibrotic kidneys after 7d UUO (0.42% ± 0.29%; 468 cells counted, n=3).
  • Supplementary Data Genbank Or OSE Vs RO NIA Accession Gene Name Symbol FC B-Value H3073C09 11.38 5.62 H3126B09 9.64 6.44 H3073B0

    Supplementary Data Genbank Or OSE Vs RO NIA Accession Gene Name Symbol FC B-Value H3073C09 11.38 5.62 H3126B09 9.64 6.44 H3073B0

    Supplementary Data GenBank or OSE vs RO NIA accession Gene name Symbol FC B-value H3073C09 11.38 5.62 H3126B09 9.64 6.44 H3073B08 9.62 5.59 AU022767 Exportin 4 Xpo4 9.62 6.64 H3073B09 9.59 6.48 BG063925 Metallothionein 2 Mt2 9.23 18.89 H3064B07 9.21 6.10 H3073D08 8.28 6.10 AU021923 Jagged 1 Jag1 7.89 5.93 H3070D08 7.54 4.58 BG085110 Cysteine-rich protein 1 (intestinal) Crip1 6.23 16.40 BG063004 Lectin, galactose binding, soluble 1 Lgals1 5.95 10.36 BG069712 5.92 2.34 BG076976 Transcribed locus, strongly similar to NP_032521.1 lectin, galactose binding, soluble 1 5.64 8.36 BG062930 DNA segment, Chr 11, Wayne State University 99, expressed D11Wsu99e 5.63 8.76 BG086474 Insulin-like growth factor binding protein 5 Igfbp5 5.50 15.95 H3002d11 5.13 20.77 BG064706 Keratin complex 1, acidic, gene 19 Krt1-19 5.06 9.07 H3007A09 5.05 2.46 H3065F02 4.84 5.43 BG081752 4.81 1.25 H3010E09 4.71 11.90 H3064c11 4.43 1.00 BG069711 Transmembrane 4 superfamily member 9 Tm4sf9 4.29 1.23 BG077072 Actin, beta, cytoplasmic Actb 4.29 3.01 BG079788 Hemoglobin alpha, adult chain 1 Hba-a1 4.26 6.63 BG076798 4.23 0.80 BG074344 Mesothelin Msln 4.22 6.97 C78835 Actin, beta, cytoplasmic Actb 4.16 3.02 BG067531 4.15 1.61 BG073468 Hemoglobin alpha, adult chain 1 Hba-a1 4.10 6.23 H3154H07 4.08 5.38 AW550167 3.95 5.66 H3121B01 3.94 5.94 H3124f12 3.94 5.64 BG073608 Hemoglobin alpha, adult chain 1 Hba-a1 3.84 5.32 BG073617 Hemoglobin alpha, adult chain 1 Hba-a1 3.84 5.75 BG072574 Hemoglobin alpha, adult chain 1 Hba-a1 3.82 5.93 BG072211 Tumor necrosis factor receptor superfamily,